Skip to main content
OpenTrials
Completed

NCT Number: NCT00531414

Inspiratory Flow Using the Osmohaler

The OsmohalerTM is a registered device in Australia. It is used to deliver a dry powder a commercial preparation of mannitol registered as AridolTM to test if a person has irritable airways such as active asthma.

The overseas regulatory authorities need to know that people of all ages can achieve an adequate inspiratory flow through this device during a controlled deep inspiration. Adequate flow is generally regarded as greater than 30 litres per minute in children and 60 litres per minute in adults. The OsmohalerTM is a device with low resistance and is already in use in Australia to deliver mannitol. However there is a need to document inspiratory flows through the device during a controlled deep inspiration. The protocol requires subjects to perform a controlled deep inspiration from the device on three or five occasions. No substance will be inhaled.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • has asthma or is healthy
  • aged 6 to 69 years inclusive
  • FEV1 >/= 70% predicted

Exclusion criteria

  • has condition contraindicating performance of spirometrt

Sponsors and collaborators

Lead sponsor

Syntara

Industry

Registry information

Official study title

Inspiratory Flow and VOlumes in Asthmatic and Healthy Individuals Using the Osmohaler

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Sep 18, 2007
Registry last updated
Apr 10, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.